摘要
B淋巴细胞刺激因子(BLys)及其同源物增殖诱导配体(APRIL)在自身免疫性肾病发病机制中起着重要作用。泰它西普是通过重组DNA技术将BLys受体TACI胞外特定的可溶部分与人IgG1 Fc段融合的蛋白,可以阻断BLys和APRIL与其细胞膜受体(TACI、BR3、BCMA)之间的相互作用,从而实现阻断BLys和APRIL的生物学作用。该文阐述了泰它西普的作用机制及其在IgA肾病、狼疮性肾炎中的疗效及其安全性和耐受性,提示泰它西普为临床治疗自身免疫性肾病提供了新的思路和方向。
B lymphocyte stimulator(BLys)and its cognate,a proliferation-inducing ligand(APRIL),play an important role in the pathogenesis of autoimmune-associated nephropathy.Telitacicept is a protein that fuses a specific extracellular soluble portion of the BLyS receptor TACI to the Fc segment of human IgG1 by recombining DNA technology,which blocks the interaction of BLys and APRIL with their cell membrane receptors(TACI,BR3,BCMA).That makes a difference in blocking the biological reactions in BLyS and APRIL.The thesis reviews the mechanism,efficacy,safety,and tolerability of Telitacicept in IgA nephropathy and lupus nephritis,suggesting that Telitacicept offers new ideas and directions for the clinical treatment of autoimmune-related nephropathy.
作者
杨佳
高洁
赵文静
徐强
李海英
于晨
董华
Jia Yang;Jie Gao;Wen-jing Zhao;Qiang Xu;Hai-ying Li;Chen Yu;Hua Dong(Department of Nephrology,Binzhou Medical University Hospital,Binzhou,Shandong 256603,China;Department of Intensive Care Medicine,Binzhou People's Hospital,Binzhou,Shandong 256601,China;Department of Laboratory,Binzhou Medical University Hospital,Binzhou,Shandong 256603,China;Department of Pharmacy,Binzhou Medical University,Yantai,Shandong 264003,China)
出处
《中国现代医学杂志》
CAS
北大核心
2022年第19期51-56,共6页
China Journal of Modern Medicine
基金
国家自然科学基金(No:81903697)。
